Kratom Explosion in the US: What the 1,200% Surge in Poisonings Means for Public Health

In 2015, poison centers across the United States fielded 258 calls about Kratom. A decade later, that number hit 3,434 [1]. That's a 1,200% increase in a single decade. The CDC's March 2026 Morbidity and Mortality Weekly Report documents the stark trajectory, tracking 14,449 Kratom-related exposure reports over the eleven-year period [1]. The numbers tell a story of a substance that has moved from obscure botanical curiosity to mainstream public health concern in the span of a generation.

The deaths tell an equally grim story. Of the 233 Kratom-associated fatalities in the CDC dataset, 184 involved multiple substances, meaning roughly four out of five deaths occurred when Kratom mixed with other drugs [1]. That multi-substance pattern runs throughout the data: hospitalization rates hit 44-56% for multi-substance cases, compared to 24-29% for single-substance exposures [1].

What's driving the explosion?

The short answer is that the Kratom market has fundamentally changed, and so has the population using it.

Researchers at Pharmacy & Biology detailed how traditional Southeast Asian Kratom consumption involves fresh leaves or teas, which produce only trace levels of 7-hydroxymitragynine (7-OH), the compound driving opioid-like effects [2]. The U.S. market is something else entirely. Sellers now market chemically enriched or semi-synthetic 7-OH products under the Kratom label, even though they are pharmacologically distinct from traditional leaf preparations [2]. These concentrated products bypass the metabolic formation that occurs with normal oral consumption, delivering dramatically higher systemic exposures of the active compound.

7-OH binds to mu-opioid receptors with nanomolar affinity, exceeding the potency of morphine in laboratory comparisons [2]. Animal studies show it produces antinociception, respiratory depression, tolerance, dependence, and reinforcing properties characteristic of opioids [2]. State health departments have reported severe intoxications and fatalities from these newer products. Forensic investigations have documented postmortem 7-OH concentrations consistent with fatal opioid toxicity [2].

The demographic of use is shifting too. While males and adults aged 20-39 still account for the most exposure reports, adults aged 40-59 showed the fastest-growing rate, and by 2025 their rates nearly overlapped with the younger group [1]. These older users often arrive at Kratom seeking pain relief or trying to manage opioid dependence, which puts them in closer contact with the health risks they were trying to avoid.

Who's most vulnerable?

Children face amplified risk. The Pharmacy & Biology analysis highlighted that pediatric populations face developmental susceptibility, encounter no age restrictions on products, and are targeted through marketing in confectionery formats [2]. Accidental ingestions in households where adults use these products represent a growing concern.

People mixing Kratom with other substances also face substantially higher danger. The CDC report found that multi-substance cases represented the vast majority of fatalities, with four out of five deaths involving concurrent substance use [1]. The drug interactions appear to amplify both the euphoric and the toxic effects, pushing users into medical emergencies they might have avoided with either substance alone.

Regular users seeking pain management or mood enhancement find themselves on a trajectory toward dependence. Clinical cases document escalating use, medically managed withdrawal, and psychiatric destabilization [2]. The Drug-Induced Liver Injury Network has documented liver damage in regular users, adding another layer of risk for those who consume Kratom frequently [3].

What are the documented health risks?

The complications span multiple organ systems. Beyond the acute poisonings and fatalities, researchers have documented Kratom-associated liver injury in regular users [3]. Cardiac effects have emerged as well, with a 2025 JACC Case Reports article describing acute right ventricular dysfunction linked to Kratom use [4].

The multi-substance deaths make clear that combining Kratom with other drugs creates compounded danger. With four out of five fatalities involving concurrent substance use [1], the data suggests that isolated Kratom consumption, while not risk-free, carries substantially lower mortality risk than polydrug use.

What are regulators doing?

Not enough, according to most public health researchers. Despite FDA concerns about Kratom's safety and abuse potential, federal scheduling has not occurred, leaving the substance in a regulatory gray area that researchers say enables widespread commercial availability [1][2].

The CDC surveillance system continues to track the rising call volume, and the agency recommends poison center reporting as a key early warning mechanism [1]. Without legislative or regulatory action at the federal or state level, however, that surveillance documents a growing problem without addressing its causes.

The 1,200% increase in poison center reports over eleven years reflects both genuine growth in Kratom use and the emergence of far more potent products in the market. What was once a traditional botanical preparation has evolved into concentrated extracts with opioid-like pharmacology. Federal oversight remains limited, commercial availability is widespread, and usage continues to spread into new populations and product categories.

The data makes clear that the health burden is real and growing. Whether the regulatory response catches up with that reality remains an open question.